And just carrying on from that, Chris, the patient reported outcome is being in a favorable -- very favorable anecdotally for treatments with mitapivat across the indication, that isn't the case with Oxbryta, notwithstanding its approval for increasing hemoglobin. And important is that the covalent bonding of [Technical Issues] haemoglobin, it prevents the sickling, so that's a very important thing. But it also lowers the ability of hemoglobins to carry oxygen. And that's very important. And we're able to preserve hemoglobin in healthier red cells such that they carry more oxygen and that there's a higher affinity of the binding for oxygen. So we believe we have actually a superior mechanism there to that of Oxbryta.